Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
This research study is investigating a drug called inebilizumab for children and adolescents between 2 and 17 years old who have a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). These young people must also have specific antibodies in their blood called AQP4-IgG. The main goals of the study are to understand how the medicine moves through the body (pharmacokinetics), what effects it has on the body (pharmacodynamics), and how safe it is. Participants will receive the medicine intravenously over 28 weeks, and their health will be closely monitored throughout the study, which could last up to 80 weeks.
De un vistazo
¿De qué trata este estudio?
This study is focused on a rare condition called Neuromyelitis Optica Spectrum Disorder, or NMOSD. It's a condition where the body's immune system mistakenly attacks its own healthy cells, particularly in the brain and spinal cord, leading to a range of symptoms. This particular study is for children and teenagers aged between 2 and 17 years old who have been diagnosed with NMOSD and have a specific type of antibody in their blood.
The research aims to find out more about a new treatment called inebilizumab. It's important to understand how new medicines work in young people because their bodies can react differently compared to adults. The study will look at how the medicine is absorbed and used by the body, what effects it has, and how safe it is for this age group.
By carefully studying inebilizumab, researchers hope to gather important information that could help in the development of new and effective treatments for children and teenagers with NMOSD in the future. This kind of research is vital for improving the lives of those affected by rare conditions.
Puntos clave
- This study is for children and teenagers with a specific type of NMOSD.
- It's testing a new medicine called inebilizumab given intravenously.
- The main goals are to check the medicine's safety and how it works in the body.
- Participation involves regular clinic visits over a period of up to 80 weeks.
- Your health will be closely monitored throughout the study.
- Puede retirarse del estudio en cualquier momento.
¿Quién puede ser elegible?
To be considered for this study, participants must be between 2 and 17 years old, weigh at least 15 kg (about 2 stone 5 pounds), and have a clear diagnosis of NMOSD. They also need to have tested positive for specific antibodies (called AQP4-IgG) in their blood and have experienced at least one NMOSD relapse in the past year, or two or more relapses in the past two years.
There are also some reasons why someone might not be able to join. For example, if they have other significant health problems affecting their liver, kidneys, or blood, or if they are currently taking part in another drug study. Also, if they have recently received certain other treatments for NMOSD or similar conditions, they might not be eligible. The study team will review all your medical information carefully to see if this study is right for you.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Are you between 2 and 17 years old?
- Do you weigh at least 15 kg?
- Have you been diagnosed with Neuromyelitis Optica Spectrum Disorder?
- Have you had a positive blood test for AQP4-IgG antibodies?
- Have you experienced an NMOSD relapse in the last year, or two or more in the last two years?
- Are you currently free from other major health issues or recent specific treatments that might prevent your participation?
¿En qué consiste la participación?
If you join this study, you would receive the study medicine, inebilizumab, directly into your vein (intravenously) over a period of 28 weeks. The study involves several visits to the clinic. First, there's a screening period of up to 4 weeks to check if you're suitable. Then, during the 28-week treatment period, you'll have about 9 visits. After that, there's a follow-up period of about 52 weeks, with approximately 4 visits to monitor your health. The total time you would be involved in the study could be up to 80 weeks (about a year and a half). Your health will be regularly checked throughout this time to ensure your safety and monitor the effects of the treatment.
Riesgos y beneficios potenciales
Locations (19)
- UCSD Altman Clinical and Translational Research Institute BuildingCódigo postal verificadoLa Jolla, Estados Unidos· Reclutamiento
- Loma Linda University Children's Hospital - PINCódigo postal verificadoLoma Linda, United States· Reclutamiento
- Hospital General de MassachusettsCódigo postal verificadoBoston, Estados Unidos· Reclutamiento
- University of Texas Southwestern Medical CenterCódigo postal verificadoDallas, United States· Reclutamiento
- Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. GarrahanCódigo postal verificadoParque Patricios, Argentina· Reclutamiento
- Hospital Santa Izabel-Rua Floriano Peixoto 300Código postal verificadoSalvador, Brazil· Reclutamiento
- Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)No verificadoPorto Alegre/RS, Brazil· Reclutamiento
- CPQuali Pesquisa Clínica Sao PauloCódigo postal verificadoSão Paulo, Brasil· Reclutamiento
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São PauloCódigo postal verificadoSão Paulo, Brasil· Reclutamiento
- Hospital For Sick ChildrenCódigo postal verificadoToronto, Canadá· Reclutamiento
- Centre Hospitalier Universitaire de BicêtreCódigo postal verificadoLe Kremlin-Bicêtre, France· Reclutamiento
- Erasmus MC Sophia Children's Hospital-Wytemaweg 80Código postal verificadoRóterdam, Países Bajos· Reclutamiento
Preguntas comunes
What is NMOSD?
NMOSD is a rare condition where your body's immune system mistakenly attacks healthy cells, mainly in the brain and spinal cord.
What is inebilizumab?
Inebilizumab is the medicine being investigated in this study. It's a potential new treatment for NMOSD that aims to help manage the condition.
¿Cómo se administrará el medicamento?
The medicine will be given directly into a vein (intravenously), meaning through a drip.
¿Cuánto tiempo estaré en el estudio?
If you join, the study participation could last for up to 80 weeks, which includes treatment and follow-up periods.
¿Puedo abandonar el estudio en cualquier momento?
Yes, you have the right to withdraw from the study at any point, and it won't affect your ongoing medical care.
Cómo obtener más información
Amgen Call Center
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.